Genetic test fine-tunes chemo decisions for early breast cancer
NCT ID NCT03961880
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study involved 270 women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Researchers wanted to see how a genetic test called Oncotype DX, which gives a Recurrence Score, influences whether doctors recommend chemotherapy. They also checked if the score relates to finding cancer cells in the bone marrow. The goal was to better understand how to personalize treatment and avoid unnecessary chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department for Women's Health
Tübingen, Baden-Wurttemberg, 72086, Germany
Conditions
Explore the condition pages connected to this study.